Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program

Sanofi and GSK's vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.